Brad A. Hartl

Brad A. Hartl

Auto-generated profile, based on publicly available information

Brad A. Hartl

Openwater, San Francisco, California, United States

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2019 in Journal of Biophotonics
Verified
Journal Article
Closed access
PDF file
AAAlba Alfonso-Garcia
Alba Alfonso-Garcia
JBJulien Bec
Julien Bec
SWShamira Sridharan Weaver
Shamira Sridharan Weaver
BHBrad Hartl
Brad Hartl
JUJakob Unger
Jakob Unger
LMLaura Marcu
Laura Marcu

21 June 2015 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
SDSebastian Dochow
Sebastian Dochow
DMDinglong Ma
Dinglong Ma
ILInes Latka
Ines Latka
Thomas W. BocklitzThomas W. Bocklitz
Thomas W. Bocklitz
BHBrad Hartl
Brad Hartl
Juergen PoppJuergen Popp
Juergen Popp

1 January 2016 in Journal of Environmental Pathology, Toxicology and Oncology
Verified
Journal Article
Closed access
PDF file
BHBrad A. Hartl
Brad A. Hartl
HHHenry Hirschberg
Henry Hirschberg
LMLaura Marcu
Laura Marcu
SCSimon R. Cherry
Simon R. Cherry
The translation of photodynamic therapy (PDT) to the clinical setting has primarily been limited to easily accessible and/or superficial diseases, for which traditional light delivery can be performed noninvasively. Cerenkov radiation, as generated from medically relevant radionuclides, has been suggested as a means to deliver light to deeper tissues noninvasively to overcome this depth limitation. This article investigates the utility of Cerenkov radiation, as generated from the radionuclide yttrium-90, for activating the PDT process using clinically approved aminolevulinic acid at 1.0 mm and also the more efficient porphyrin-based photosensitizer mesotetraphenylporphine with two sulfonate groups on adjacent phenyl rings (TPPS2a) at 1.2 µm. Experiments were conducted with monolayer cultured glioma and breast tumor cell lines. Although aminolevulinic acid proved to be ineffective for generating a therapeutic effect at all but the highest activity levels, TPPS2a produced at least a 20% therapeutic effect at activities ranging from 6 to 60 µCi/well for the C6 glioma cell line. Importantly, these results demonstrate for the first time, to our knowledge, that Cerenkov radiation generated from a radionuclide can be used to activate PDT using clinically relevant photosensitizers. These results therefore provide evidence that it may be possible to generate a phototherapeutic effect in vivo using Cerenkov radiation and clinically relevant photosensitizers.

10 February 2015 in Biomedical Optics Express
Verified
Journal Article
Open access
PDF file
BHBrad A. Hartl
Brad A. Hartl
HHHenry Hirschberg
Henry Hirschberg
LMLaura Marcu
Laura Marcu
SCSimon R. Cherry
Simon R. Cherry
The translation of photodynamic therapy (PDT) to the clinic has mostly been limited to superficial diseases where traditional light delivery is noninvasive. To overcome this limitation, a variety of mechanisms have been suggested to noninvasively deliver light to deep tissues. This work explores the minimum amount of light required by these methods to produce a meaningful PDT effect in the in vitro setting under representative low fluence and wavelength conditions. This threshold was found to be around 192 mJ/cm2 using the clinically approved photosensitizer aminolevulinic acid and 12 mJ/cm2 for the more efficient, second generation photosensitizer TPPS2a.

1 July 2012 in IEEE Journal of Selected Topics in Quantum Electronics
Verified
Journal Article
Closed access
LMLaura Marcu
Laura Marcu
BHB. A. Hartl
B. A. Hartl
Clinical outcome of patients diagnosed with primary brain tumor has been correlated with the extent of surgical resection. In treating this disease, the neurosurgeon must balance between an aggressive, radical resection and minimizing the loss of healthy, functionally significant brain tissue. Numerous intraoperative methodologies and technological approaches have been explored as a means to improve the accuracy of surgical resection. This paper presents an overview of current conventional techniques and new emerging technologies with potential to impact the area of image-guided surgery of brain tumors. Emphasis is placed on techniques based on endogenous fluorescence lifetime contrast and their potential for intraoperative diagnosis of brain tumors.

1 January 2024 in Neurophotonics
Verified
Journal Article
Open access
PDF file
CFChristopher G. Favilla
Christopher G. Favilla
SCSarah Carter
Sarah Carter
BHBrad Hartl
Brad Hartl
RGRebecca Gitlevich
Rebecca Gitlevich
MMMichael T. Mullen
Michael T. Mullen
SKSoren Konecky
Soren Konecky
Quantification of cerebral blood flow (CBF) at the bedside holds potential to inform and improve care for a wide range of neurologic diseases, perhaps most notably ischemic stroke in which CBF optimization is a pillar of clinical management. Unfortunately, technical limitations of existing methods for CBF quantification severely impede their clinical utility. The gold standard for non-invasive CBF imaging is O15-positron emission tomography (PET),1,2 but O15-PET is logistically complicated, expensive, and exposes the patient to ionizing radiation. Advanced MRI and CT based techniques can quantify CBF, but they provide only snapshots of data and are not suitable for serial bedside monitoring.3 – 7 Invasive tissue monitors, such as the Bowman Perfusion Monitor®, provide real-time physiologic data, including CBF,8 but they are too invasive to be practical in most clinical contexts. Thus, development and translation of a non-invasive bedside modality for CBF measurement is needed.